Highlights Assays reported for a further 9 drill holes for 4,007m of diamond drilling.Consistent drill results with excellent localized higher-grade zones providing a potential opportunity for higher-grade mine scheduling within the wider mineral resource envelope.Notable drill intercepts from the holes include: HM103: 74m @ 0.36% Cu (66 to 140m) incl. 16m @ 0.56% Cu (106 to 122m) HM102: 19m @ 0.64% Cu (204 to 223m) HM107: 18m @ 0.45% Cu (12 to 30m) HM104: 26m @ 0.36% Cu (220 to 246m)214m @ 0.34% Cu (272 ...

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, announces that the Company has issued stock options. The Company has granted 950,000 incentive stock options to directors, officers and senior employees of the Company. The stock options are exercisable for a period of 10 years at an exercise price of CAD$0. ...

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced PensionBee Group plc (LON: PBEE; OTCQX:PBNYF), a leading online retirement savings provider, has qualified to trade on the OTCQX® Best Market. PensionBee Group plc begins trading today on OTCQX under the symbol “PBNYF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcma ...

Core Insights - Relay Therapeutics announced interim clinical data for zovegalisib, an investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα, showing promising efficacy in patients with metastatic breast cancer [1][10] Efficacy Data - The median progression-free survival (PFS) was reported as 10.3 months for all patients and 11.4 months for second-line (2L) patients [6] - Among patients with measurable disease, the objective response rate (ORR) was 39%, while the ORR for 2L patients was 47% [6] - Efficacy was consistent across various subsets, with a median PFS of 11.4 months and ORR of 44% for patients who received prior SERD [7] Patient Population - As of October 15, 2025, 118 patients were enrolled in the zovegalisib + fulvestrant arm of the ReDiscover study, with significant prior therapy levels noted [4] - Among the 64 patients receiving 600mg twice daily, 44% had two or more prior lines of therapy, and 29% had detectable ESR1 mutations at baseline [4] Ongoing Trials - The Phase 3 ReDiscover-2 trial is ongoing, focusing on zovegalisib + fulvestrant in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- advanced breast cancer [8] - The ReDiscover trial is also evaluating zovegalisib in combination with fulvestrant and CDK inhibitors [3] Company Overview - Relay Therapeutics is a clinical-stage company focused on developing precision medicine therapies for cancer and genetic diseases, with zovegalisib being its lead program [12] - The company utilizes its Dynamo platform to discover and develop mutant-selective inhibitors of PI3Kα, addressing a significant patient population in the U.S. [10][12]

Figure 1 Novartis executives, federal, state and local officials gather for a groundbreaking at the company's flagship manufacturing hub in Durham, North Carolina, Thursday, December 11, 2025 Figure 2 Novartis CEO Vasant (Vas) Narasimhan, MD, pictured with North Carolina Governor Josh Stein at the company's flagship manufacturing hub groundbreaking in Durham, NC, Thursday, December 11, 2025 FDA Commissioner Marty Makary, North Carolina Governor Josh Stein and Novartis leadership highlight importance ...

Core Viewpoint - Stallion Uranium Corp. is initiating a non-brokered private placement to raise up to $4.55 million through the issuance of flow-through shares at a price of $0.45 per share, aimed at funding eligible Canadian exploration expenses related to its uranium projects in the Athabasca Basin, Saskatchewan [1][2]. Group 1: Offering Details - The private placement will consist of flow-through shares, which are defined under the Income Tax Act (Canada), and the gross proceeds will be used for qualifying expenditures related to uranium exploration [1][2]. - The offering is subject to approval from the TSX Venture Exchange, and all securities distributed will have a hold period of four months and one day following the closing date [3]. Group 2: Use of Proceeds - The funds raised will be allocated to incur eligible "Canadian exploration expenses" that qualify as "flow-through critical mineral mining expenditures" for the company's uranium projects, with all qualifying expenditures to be renounced in favor of the subscribers effective December 31, 2025 [2]. Group 3: Company Overview - Stallion Uranium Corp. is focused on uranium exploration in the Athabasca Basin, which is known for having the largest high-grade uranium deposits globally, covering approximately 1,700 square kilometers [5]. - The company, in partnership with Atha Energy, holds the largest contiguous project in the Western Athabasca Basin, adjacent to multiple high-grade discovery zones, and is committed to responsible exploration using advanced technology [5].

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced results from the Asian subset (n=488) of its global Phase 3 DUBLIN-3 trial eval ...

–ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older–-Oral pellet formulation provides child-friendly method of administration- –Showed early and sustained reductions in monthly attack rates in APeX-P– RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for the use of an oral pellet formulation ...

Financial Calendar 2026 - Danish Ship Finance A/S Attachment No. 17 - Financial calendar ...

Core Viewpoint - Ellomay Capital Ltd. has successfully secured a tariff for its solar project "Ellomay 14" in Italy, enhancing its commercial presence in the renewable energy sector and ensuring long-term revenue stability through a favorable pricing arrangement [1][4]. Project Details - The Ellomay 14 project has a peak capacity of 20 MWp and is expected to generate approximately 32,200 MWh annually [2]. - The project was awarded an operating fixed price of €68/MWh, with an additional regional supplement of €10/MWh, resulting in a total supported price of €78/MWh [2]. - The award includes a 20-year two-way Contract for Difference (CfD), providing price stability for 80% of the project's total production [3]. Financial Implications - The total expected revenue for the Ellomay 14 project over the 20-year duration of the FER X "NZIA" is approximately €55 million [3]. - The awarded tariff is indexed to the Italian CPI at 100% from the tender publication date until the project's commercial operation date, and 20% indexed to the CPI thereafter, enhancing revenue predictability [3]. Strategic Positioning - This award marks Ellomay's second successful result in the FER X tender process, following the award for the 79.5 MWp Ellomay 11 project [4]. - The company has a diversified portfolio in Italy, including 38 MW of operational projects and 210 MW that have reached Ready-to-Build status [5]. Leadership Insights - The CEO of Ellomay emphasized the importance of the award in reinforcing the company's commercial framework in Italy and its strategy of developing projects that offer stable, long-term value [6].